<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012193</url>
  </required_header>
  <id_info>
    <org_study_id>GNUHIRB-2009-24</org_study_id>
    <nct_id>NCT01012193</nct_id>
  </id_info>
  <brief_title>Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism</brief_title>
  <acronym>ACCEL-2C19</acronym>
  <official_title>CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of adjunctive cilostazol versus high
      maintenance-dose clopidogrel on platelet inhibition in carriers and non-carriers of the
      loss-of-function CYP2C19 mutant allele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The additional platelet inhibition with clopidogrel, a thienopyridine inhibitor of the
      platelet P2Y12 adenosine diphosphate (ADP) receptor, has reduced the risk of ischemic events
      after coronary stent implantation. Because of inter-individual variability in platelet
      response to clopidogrel, a significant proportion of suboptimal platelet inhibition has been
      reported. In addition, persistent residual platelet reactivity measured with platelet
      function testing has shown the association with the cardiovascular outcomes after
      percutaneous coronary intervention (PCI).

      Various clinical factors and genetic polymorphisms have been studied to predict the degree of
      antiplatelet response to clopidogrel. Interestingly, recent studies found that carriers of
      the loss-of-function hepatic cytochrome (CYP) 2C19 allele had significantly lower levels of
      the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of
      major adverse cardiovascular events than did non-carriers, in the setting of PCI and acute
      coronary syndrome (ACS). These findings raise the need of solutions to overcome enhanced
      post-clopidogrel platelet reactivity by the influence of the loss-of-function CYP2C19 allele.
      Increasing the dose of clopidogrel and new potent P2Y12 antagonists (such as prasugrel) may
      be alternative antiplatelet regimens in patients with the loss-of-function CYP variant.

      Cilostazol reversibly induces platelet inhibition via its blockade of phosphodiesterase (PDE)
      type 3 and is catalysed mainly by CYP3A. A recent study demonstrated that adjunctive
      cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) intensified platelet
      inhibition as compared with a high maintenance-dose (MD) of 150 mg/day. Therefore, triple
      antiplatelet therapy could also be an alternative antiplatelet therapy to improve platelet
      inhibition and clinical outcomes in carriers of CYP2C19 mutant allele.

      We compared the enhanced inhibition of platelet aggregation by adjunctive cilostazol 100 mg
      twice daily versus high-MD clopidogrel 150 mg/day in patients treated with elective coronary
      stenting, according to the CYP2C19 polymorphism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of maximal platelet aggregation according to CYP 2C19 polymorphism</measure>
    <time_frame>30-day therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of late platelet aggregation, reduction of P2Y12 reaction unit, and the rate of high post-clopidogrel platelet reactivity according to CYP 2C19 polymorphism</measure>
    <time_frame>30-day therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>adjunctive cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjunctive cilostazol 100mg bid to dual antiplatelet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high maintenance-dose clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double dose of clopidogrel 150mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol 100mg bid or clopidogrel 150-mg daily</intervention_name>
    <description>Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily</description>
    <arm_group_label>adjunctive cilostazol</arm_group_label>
    <arm_group_label>high maintenance-dose clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Significant coronary artery stenosis (&gt;70% by visual estimate)

          -  Elective coronary stent implantation

        Exclusion Criteria:

          -  Acute myocardial infarction

          -  Active bleeding and bleeding diatheses

          -  Hemodynamic instability

          -  Oral anticoagulation therapy with warfarin

          -  Use of peri-procedural glycoprotein IIb/IIIa inhibitors

          -  Contraindication to antiplatelet therapy

          -  Left ventricular ejection fraction &lt; 30%

          -  Leukocyte count &lt; 3,000/mm3, platelet count &lt; 100,000/mm3, AST or ALT ≥ 3 times upper
             normal

          -  Serum creatinine level ≥ 3 mg/dL

          -  Stroke within 3 months

          -  Noncardiac disease with a life expectancy &lt; 1 year

          -  Inability to follow the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20823393</url>
    <description>Pubmed release of ACCEL study</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>May 15, 2011</last_update_submitted>
  <last_update_submitted_qc>May 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Young-Hoon Jeong/Assisstant professor</name_title>
    <organization>Gyeongsang National University Hospital</organization>
  </responsible_party>
  <keyword>adjunctive cilostazol</keyword>
  <keyword>high-MD clopidogrel</keyword>
  <keyword>CYP 2C19 polymorphism</keyword>
  <keyword>high risk patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

